Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised study
{{output}}
Background: Burosumab, a human anti-fibroblast growth factor 23 monoclonal antibody, is approved in Europe for treating X-linked hypophosphataemia (XLH) in patients aged at least 1 year. Early initiation might further improve cli... ...
